Including information on the therapeutic window in bioequivalence acceptance

Pharmaceutical Research

Volumn 25, Issue 11, 2008, Pages 2628-2638

  Jacobs, Tom ^a   De Ridder, Filip ^b   Rusch, Sarah ^b   Van Peer, Achiel ^b   Molenberghs, Geert ^a,c   Bijnens, Luc ^b  

^a HASSELT UNIVERSITY   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Average bioequivalence; Bioavailability; Individual bioequivalence; Therapeutic window

Indexed keywords

DIGOXIN; PHENYTOIN; THEOPHYLLINE;

ARTICLE; BIOEQUIVALENCE; DOSE RESPONSE; DRUG EFFECT; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; SIMULATION;

DIGOXIN; HUMANS; MAXIMUM TOLERATED DOSE; PHENYTOIN; THEOPHYLLINE; THERAPEUTIC EQUIVALENCY;

EID: 53849128834     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9680-6     Document Type: Article

References (23)

1. S. Anderson W. Hauck 1990 Consideration of individual bioequivalence J. Pharmacokinet. Biopharm. 18 3 259 273
2. F. Bochner D. Huffman D. Shen D. Azarnoff 1977 Bioavailability of digoxin-hydroquinone complex: A new oral digoxin formulation J. Pharm. Sci. 66 5 644 647
3. A. Boddy F. Snikeris R. Kringle G. Wei J. Opperman K. Midha 1995 An approach for widening the bioequivalence limits in the case of highly variable drugs Pharm. Res. 12 1865 1868
4. Committee for Proprietary Medicinal Products (CPMP), the European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on the investigation of bioavailability and bioequivalence. (2001).
5. Committee for Proprietary Medicinal Products (CPMP), the European Agency for the Evaluation of Medicinal Products (EMEA). Concept paper for an addendum to the note for guidance on the investigation of bioavailability and bioequivalence: evaluation of bioequivalence of highly variable drugs and drug products. (2006).
6. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products- General Considerations. (2003).
7. M. Gibaldi, and D. Perrier. Pharmacokinetics. New York, Marcel Dekker, (1982).
8. F. Hsuan 2000 Some statistical considerations on the FDA draft guidance for individual bioequivalence Stat. Med. 19 2879 2884
9. V. Karalis M. Symillides P. Macheras 2004 Novel scaled average bioequivalence limits based on GMR and variability considerations Pharm. Res. 21 10 1933 1942
10. V. Karalis P. Macheras M. Symillides 2005 Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties Eur. J. Pharm. Sci. 26 1 54 61
11. P. Macheras A. Rosen 1983 The bioequivalence factor Pharm. Acta Helvetiae. 58 8 233 236
12. M. C. Meyer A. B. Straughn R. M. Mhatre 2001 Variability in the bioavailability of phenytoin capsules in males and females Pharm. Res. 18 394 397
13. Ministry of Health, Canada. Bioequivalence requirements: critical dose drugs. Ministry of Health, Canada, 2006.
14. G. Mistry A. Laurent A. Sterrett P. Deutsch 1999 Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects J. Clin. Pharmacol. 39 636 642
15. D. Martin D. Tompson S. Boike D. Tenero B. Ilson D. Citerone D. Jorkasky 1997 Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers Br. J. Clin. Pharmacol. 43 661 664
16. J. O'Quigley M. Pepe L. Fisher 1990 Continual reassessment method: a practical design for phase I clinical trials in cancer Biometrics. 46 33 48
17. S. Patterson S. Francis M. Ireson D. Webber J. Whitehead 1999 A novel Bayesian decision procedure for early-phase dose finding studies J. Biopharm. Stat. 9 583 597
18. J. Pinheiro, and D. Bates. Mixed-effects models in S and S-PLUS. Springer, Berlin, 2000.
19. D. Santos Buelga, M. J. Garcia, M. J. Otero, A. Martin Suarez, A. Dominguez-Gil, and J. C. Lukas. Phenytoin covariate models for Michaelis-Menten pharmacokinetics in adult epileptic patients. Page meeting, Paris, (2002).
20. L. B. Sheiner 1992 Bioequivalence revisited Stat. Med. 11 1777 1788
21. D. J. Schuirmann 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the average bioavailability J. Pharmacokinet. Biopharm. 15 657 680
22. V. Steinijans R. Sauter D. Hauschke E. Diletti R. Schall H. Luus M. Elze H. Blume C. Hoffmann G. Franke W. Siegmund 1995 Reference tables for the intrasubject coefficient of variation in bioequivalence studies Int. J. Clin. Pharmacol. Ther. 33 427 430
23. J. Wagner. Fundamentals of clinical pharmacokinetics. Drug Intelligence, Hamilton, 1975.